Does complexation with copper(II) improve pharmacological properties of sulfadiazine?

JUAN J. MARTÍNEZ MEDINA; CRISTIAN VILLA-PÉREZ; JUAN F. CADAVID-VARGAS; ANA L. DI VIRGILIO; DELIA B. SORIA

Mar del Plata

Congreso; Reunión Anual de Sociedades de Biociencias 2023; 2023

Sociedad Argentina de Investigación Clínica (SAIC), Sociedad Argentina de Inmunología (SAI) y Sociedad Argentina de Fisiología (SAFIS)

The main purpose of this study was to synthesize a ternary Cu(II) complex of sulfadiazine (SDZ) - an antibacterial and antimalarial drug - which includes the 2,2′-bipyridine (bipy) as co-ligand, named Cu(SDZ)bipyCl. The assessment of this complex´s toxicological along with the antimicrobial and antitumor features is reported here. Our findings showed that this complex induces neither mutagenicity (Ames Test) nor acute toxicity on A. salina nauplii (until 600 µg mL-1). Besides, the ligand SDZ showed MIC values with clinical relevance against five strains (P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. aureus ATCC 25923, S. aureus ATCC 29213, and C. krusei). The complex showed relevant antimicrobial activity against these strains and other additional ATCC strains (S. epidermidis, E. faecalis, C. albicans, and C. parapsilosis) and clinical isolates (Escherichia, Staphylococcus, and Candida genus). Moreover, the complex showed a harmful effect in human osteosarcoma and human lung carcinoma cell lines with a concentration-dependent behaviour from 10 to 100 μM.